Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Drug Safety Office Is Already Independent, CDER Director Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting CDER Director Galson responds to calls for greater independence of drug safety functions by noting that both the Office of Drug Safety and Office of New Drugs report directly to him. FDA will “continue its longstanding practice of assessing the safety of all drugs” using “sound science,” Galson says.

You may also be interested in...



FDA's Crawford Open To Discussing Independent Drug Safety Office

Acting Commissioner Crawford tells members of the Senate Health Committee during his confirmation hearing that he is willing to talk about a more independent safety review office. However, the commissioner nominee also says the Office of Drug Safety already is "operating independently."

FDA's Crawford Open To Discussing Independent Drug Safety Office

Acting Commissioner Crawford tells members of the Senate Health Committee during his confirmation hearing that he is willing to talk about a more independent safety review office. However, the commissioner nominee also says the Office of Drug Safety already is "operating independently."

FDA Authority To Require Rx Label Changes Would Be "Helpful," Kweder Says

Officer of New Drugs Deputy Director Kweder tells Senate Health Committee that the agency lacks the ability to dictate the contents of drug labeling, but that the power to do so "would be very helpful." Kweder notes it took over a year to negotiate the addition of cardiovascular risk information to Merck's Vioxx.

Related Content

Topics

UsernamePublicRestriction

Register

PS058183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel